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Immune system deregulation in 
hypertensive patients chronically 
RAS suppressed developing 
albuminuria
Marta Martin-Lorenzo1, Laura Gonzalez-Calero1, Paula J. Martinez1, Montserrat Baldan-
Martin2, Juan Antonio Lopez3, Gema Ruiz-Hurtado4, Fernando de la Cuesta2, Julián Segura4, 
Jesús Vazquez3, Fernando Vivanco1,5, Maria G. Barderas2, Luis M. Ruilope4,6 & Gloria Alvarez-
Llamas1
Albuminuria development in hypertensive patients is an indicator of higher cardiovascular (CV) risk 
and renal damage. Chronic renin-angiotensin system (RAS) suppression facilitates blood pressure 
control but it does not prevent from albuminuria development. We pursued the identification of protein 
indicators in urine behind albuminuria development in hypertensive patients under RAS suppression. 
Urine was collected from 100 patients classified in three groups according to albuminuria development: 
(a) patients with persistent normoalbuminuria; (b) patients developing de novo albuminuria; (c) 
patients with maintained albuminuria. Quantitative analysis was performed in a first discovery cohort 
by isobaric labeling methodology. Alterations of proteins of interest were confirmed by target mass 
spectrometry analysis in an independent cohort. A total of 2416 proteins and 1223 functional categories 
(coordinated protein responses) were identified. Immune response, adhesion of immune and blood 
cells, and phagocytosis were found significantly altered in patients with albuminuria compared to 
normoalbuminuric individuals. The complement system C3 increases, while Annexin A1, CD44, S100A8 
and S100A9 proteins showed significant diminishment in their urinary levels when albuminuria is 
present. This study reveals specific links between immune response and controlled hypertension 
in patients who develop albuminuria, pointing to potential protein targets for novel and future 
therapeutic interventions.
Urinary albumin excretion is an indicator of worse cardiovascular prognosis, independently of renal function 
or diabetes1–3. Particularly in hypertensives, clinical guidelines recommend the use of albuminuria to assess tar-
get organ damage4, and recent studies point to its value not only in cardiovascular (CV) risk stratification but 
also in predicting individual prognosis or assessing therapeutic efficiency5. The ability of renin-angiotensin sys-
tem (RAS) suppression to control blood pressure in hypertensive individuals has been amply demonstrated6–8. 
However, recent studies conducted by our group and others showed high albuminuria development in a relevant 
percentage of patients undergoing chronic RAS suppression, either as maintained (MHA) or as de novo developed 
albuminuria (dnA)5, 9. These patients are likely at the highest risk of progression of CV and renal disease. The 
reason why some of these controlled hypertensive individuals develop albuminuria and others do not, persistant 
normoalbuminuric patients (N), is uncertain. Subjacent physiopathological alterations are unknown and this 
phenomenon is difficult to predict and avoid.
1Departament of Immunology, IIS-Fundacion JimenezDiaz, REDinREN, Madrid, Spain. 2Department of Vascular 
Physiopathology, Hospital Nacional de Paraplejicos SESCAM, Toledo, Spain. 3Laboratory of Cardiovascular 
Proteomics CNIC, Madrid, Spain. 4Hypertension Unit, Instituto de Investigación imas12, Hospital Universitario 12 de 
Octubre, Madrid, Spain. 5Department of Biochemistry and Molecular Biology I, Universidad Complutense, Madrid, 
Spain. 6Universidad Europea, Madrid, Spain. Marta Martin-Lorenzo and Laura Gonzalez-Calero contributed equally 
to this work. Correspondence and requests for materials should be addressed to L.M.R. (email: ruilope@ad-hocbox.
com) or G.A.-L. (email: galvarez@fjd.es)
Received: 13 April 2017
Accepted: 19 July 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC REPORTS | 7: 8894  | DOI:10.1038/s41598-017-09042-2
Immune response was linked to hypertension, together with inflammation, far beyond CV disease. 
Participation of immune cells in hypertension was demonstrated and also the efficiency of immunosuppressants 
in BP diminishment in animal models10, 11. Vaccination was even tentatively proposed as a future therapy for 
prevention12, 13. Previous findings point to the immune system in modulation of renal injury14. In particular, an 
increased number of infiltrating immune cells was observed in this organ in experimental hypertensive models15. 
Our group recently identified urinary CD59, an inhibitor of the membrane attack complex (MAC) to protect 
cells in an inflammatory scenario, and a sub-set of plasma immunoglobulins as key molecules behind physio-
pathological mechanisms responsible for albuminuria development in hypertensive patients under chronic RAS 
suppression16, 17.
Urine composition not only reflects normal kidney function but also contains specific proteins produced 
in the kidney which may be altered in response to CV disease18, diabetic nephropathy19, and chronic kidney 
disease20, among others21. Here, we pursued the identification of protein indicators detectable in urine linked 
to albuminuria development in hypertensive patients under chronic RAS suppression. For such purpose, we 
screened the urinary proteome widely by using a non-biased (non-target) quantitative approach based on peptide 
labelling (iTRAQ methodology) and highly sensitive mass spectrometry detection (MS).
Results
This study extends our previous knowledge in the search for urinary protein alterations in hypertensive patients 
who develop albuminuria despite of chronic RAS suppression. Continuous development of proteomic tools 
allows to widely cover the urinome and detect differences otherwise hidden. In this sense, a highly-sensitive and 
quantitative protein analysis has been performed in urine in this clinical setting. Urinary changes were inves-
tigated by a double approach: 1) shotgun data revealed individual proteins with altered levels in albuminuric 
patients (dnA or MHA vs N); and 2) systems biology analysis revealed biological processes (functional catego-
ries) altered as the result of coordinated protein responses (Supplementary Figure 1). Identification of significant 
alterations was approached as detailed in methods section for both, individual proteins and biological processes. 
A detailed workflow is shown in Fig. 1. All proteomics data derived from this study are deposited in Peptide Atlas 
and are accessible through the accession number PASS01069.
Immune response: a main alteration in hypertensives under chronic RAS suppression devel-
oping albuminuria. In the shotgun experiment, a total of 2416 proteins were identified (Supplementary 
Table 1). Albumin was identified with the expected increase in dnA and MHA vs N. CD59 and alpha-1 antitrypsin 
also confirmed their variation in urine of albuminuric hypertensives under chronic RAS suppression as previ-
ously published by our group17. A total of 1223 categories (biological processes) were identified (Supplementary 
Table 2). When this double approach was merged, four categories related to immune response highlight: “immune 
response of cells”, “adhesion of immune cells”, “adhesion of blood cells” and “phagocytosis” (Table 1). A total of 70 
unique proteins compose these functional categories (see Supplementary Tables 3–6 showing individual protein 
responses). As expected, some proteins are shared by various categories. In particular, 23 proteins are categorized 
in immune response of cells in albuminuric individuals. Interaction networks analysis relate them with specific 
Figure 1. Schematic workflow showing the different parts of the study from patients selection to discovery and 
confirmation stages.
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molecular processes. In particular, ANXA1, CLEC7A, DOCK2, and CD4 are involved in T-cells activation and 
differentiation; dendritic cells regulation involves GAS6 and PRTN3; and ANXA1, AZU1, C3, GAS6, CSF1, 
CD14, CD4 and THBS1 participate in cytokine production and regulation.
Adhesive interactions mediate migration of cells to sites of inflammation. Adhesion is mediated by specific 
molecules, called adhesion molecules, which are classified mainly in terms of their dependence of calcium. 
Adhesion of immune cells and blood cells categories content 45 and 55 proteins, respectively. Regarding to cal-
cium independent proteins, the MAC (membrane attack complex) proteins: MCAM, ICAM, PECAM and VCAM 
showed reduced urinary levels in albuminuric patients. VCAM1 mediates the adhesion of lymphocytes, mono-
cytes, eosinophils and basophils while ICAM1 do the same for inflammatory immune cells as macrophages and 
granulocytes. Both of them cluster with activated moesin and ezrin22, which were found here with contrary trend 
to the MAC proteins (increased levels in albuminuric individuals).
Phagocytosis is an essential part of the immune response, both, innate and adaptive, also involved in tissue 
remodeling and homeostasis23. Phagocytosis promotes the release of pro-inflammatory cytokines24 and 25 pro-
teins were here identified in urine linked to this process. Mainly, binding proteins as CAMP, CLEC7A, CSF1, 
CALR, DOCK2, SWAP70, ASAP2, C3 and GAS6; and proteins with catalytic activity as CAMP, DOCK2, AZU, 
AHSG, ASAP2, PRTN3 and C3. Figures 2 and 3 represent the 70 proteins and their role in immune response. 
Protein variation rate in dnA or MHA compared to N are represented.
Specific protein signatures reveal immune deregulation. Individual variation of immune system 
proteins in response to albuminuria development was evaluated and five proteins were selected with signifi-
cant variation in dnA and MHA compared to N (variation rate ≥ |2| and a minimum of 3 peptides identified) 
(Table 2). Significantly altered proteins are: the complement system protein C3, found increased, and Annexin 
A1 (ANXA1), S100A8, S100A9, and the glycoprotein CD44, found decreased. In particular, adhesion of blood 
cells comprises ANXA1, CD44, C3, S100A8 and S100A9; adhesion of immune cells comprises ANXA1, CD44, 
S100A8 and S100A9; and immune response of cells and phagocytosis includes ANXA1 and C3 (Figs 2 and 3). 
These five proteins were confirmed by target mass spectrometry (SRM-LC-MS/MS) in an independent cohort 
of 63 hypertensive individuals as shown in Fig. 4 (Supplementary Table 7). Receiver operating curves (ROC) are 
shown in Fig. 5. Individual ROC curves show good sensitivity and specificity which is considerably improved 
when individual responses are combined (see also Supplementary Figure 2). Correlations with albuminuria were 
also calculated showing significant correlation in all cases (Fig. 6).
Discussion
One of the main challenges in the management of hypertensive patients under chronic suppression of RAS is 
understanding why some of them develop albuminuria and thus have a worse prognosis. The link between hyper-
tension and immune system has been revised25, mainly based on models of genetic hypertension (spontaneously 
hypertensive rats, SHR), induced hypertension with DOCA/salt, Angiotensin II or renal damage. Here we applied 
a non-target analysis combined with a recenlty developed algorithm designed for system biology analysis. In this 
way, we could achieve a wide coverage of the urinary proteome and identify coordinated protein behaviour in 
response to albuminuria development in hypertensives under RAS suppression. Immune response alteration was 
identified in terms of immune response of cells, phagocytosis, and cell adhesion. In particular, main alterations 
were identified for the proteins C3, CD44, ANXA1, S100A8 and S100A9.
The cell mediated immunity involves activation of T-lymphocytes, macrophages and natural killer cells, 
and the release of cytokines in response to an antigen. Alterations of such immune response here detectable 
in urine comprise 23 proteins (Figs 2 and 3). Among them, the two most contributing are C3 and ANXA1. C3 
levels are increased in plasma during hypertension development26 and it is even higher in patients with resist-
ant hypertension27. High levels of C3 correlated with higher risk of developing hypertension, diabetes or myo-
cardial infarction28. Our findings are also consistent with a local synthesis of C3 from renal epithelial cells in 
proteinuria-associated renal disease29. In this sense, C3 deposits were found in proximal tubular cells in kidneys 
of proteinuric patients30, in agreement with an excess protein traffic occurring in proteinuric nephropathies, 
causing an inflammatory response with local increase of C331. Reduced expression of ANXA1 was observed 
in aortas from MgL mice with low intracellular magnesium levels (and high blood pressure)32. ANXA1 is an 
endogenous repressor of inflammation and increased urinary levels have been linked to glomerular injury. 
However, our patients do exhibit mildly decreased eGFR, thus observed reduced levels in urine may suggest an 
impaired compensation of inflammation by ANXA1 in albuminuric patients. C3 and ANXA1 also play a key role 
Biological Process
dnA/N MHA/N
Z FDR Total proteins Z FDR Total proteins
Adhesion of blood cells −3.44 0.03 55 −2.97 0.09 55
Adhesion of immune cells −3.40 0.03 45 −3.03 0.08 45
Immune response of cells −3.47 0.03 23 −3.54 0.02 23
Phagocytosis −3.40 0.03 25 −3.56 0.02 25
Table 1. Immune response categories significantly altered in hypertensive patients under chronic RAS 
suppression who develop albuminuria. A negative Z value indicates down-regulation in dnA or MHA versus N. 
The number of proteins included in each biological process (categories) is also indicated. N: normoalbuminuria; 
dnA: de novo albuminuria; MHA: maintained high albuminuria.
www.nature.com/scientificreports/
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in phagocytosis in different cells and diseases, such as the phagocytosis of apoptotic leukocytes during peripheral 
inflammation33 or the macrophage mediated phagocytosis of apoptotic cells for clearance34. Here we show clear 
de-regulation of these proteins in response to albuminuria development.
Cell adhesion was also shown to be deregulated. Adhesive interactions mediate migration of cells to sites of 
inflammation. In particular, CD44 is a calcium-independent adhesion molecule that participates in lymphocyte 
activation. Recent studies propose that high levels of AngII promote an increase in circulating levels of CD4435, 
and that inhibiting CD44 interaction with hyaluronic acid would be useful as therapeutic target by reducing the 
negative CV effects of Ang II36. Here, we found a reduction in CD44 urine levels in albuminuric patients RAS 
suppressed.
Figure 2. Functional categories related to immune response showing significant alteration between dnA and N 
(Z value ≥ |2|, FDR < 0.05). Variation rates for each individual protein are shown. dnA: de novo albuminuria, N: 
normoalbuminuria.
www.nature.com/scientificreports/
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Finally, S100A8 and S100A9 are two calcium-binding proteins that constitute a heterodimer called calpro-
tectin with high affinity not only for calcium but also for zinc and magnesium, playing an important role in the 
metal availability in immune system. Increased levels were found in cardiac tissue microarrays, heart and heart 
neutrophils when AngII is infused37. S100A8 was severely diminished in monocytes from acute coronary syn-
drome patients compared to healthy controls38. These two proteins have different roles as scavenging reactive 
oxygen species or contribution to phagocytosis39. In particular, calprotectin inhibits MMPs whose activity was 
found increased previously by our group in this clinical scenario in agreement with reduced levels observed here 
for these two proteins40.
Apart from these main protein alterations, when looking for the interactions among the 70 unique pro-
teins identified related to immune response, 41 proteins are interconnected (see the immune network behind 
Figure 3. Functional categories related to immune response showing significant alteration between MHA and 
N (Z value ≥ |2|, FDR < 0.05). Variation rates for each individual protein are shown. MHA: maintained high 
albuminuria, N: normoalbuminuria.
www.nature.com/scientificreports/
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albuminuria development in Supplementary Figure 3). Fourteen proteins substantially varied already in dnA 
(earlier response), constituting a molecular fingerprint which deserves particular attention for further confirma-
tion in subsequent studies. Particularly, CD59 was already identified in a previous study from our group with the 
same trend by a different technical approach. We found vimentin altered in the intima and media layers from ath-
erosclerotic coronary pointing to cytoskeleton disassembly41, 42. APOH was pointed as a potential clinical marker 
of cardiovascular disease43. Thioredoxin plays a role in cellular defense against oxidative stress in cardiovascular 
disease44 and reverses age-related hypertension attenuating endothelial dysfunction and increasing nitric oxide 
production45.
Albuminuria is currently the key indicator to follow for an early intervention in these hypertensive patients 
who are under chronic RAS suppression, aimed to prevent from chronic kidney disease (CKD) development. 
Previously, we identified specific proteins in plasma associated with albuminuria development which point to the 
activation of the immune system16. This study widely covers the urinary proteome in the context of hypertensive 
patients who develop albuminuria despite of chronic RAS suppression. Main subjacent alterations in terms of 
biological processes underlying albuminuria development involve immune cells and immune response of cells. 
Thus, we further confirm the link between immune system and hypertension. Specific protein signatures linked 
to albuminuria development and to be targeted in future therapeutic interventions have been confirmed, and 
further studies should follow to investigate additional proteins of potential interest. The role of immune system 
in this clinical context is here clearly manifested. As main weakness to be acknowledged is the limited number of 
patients. The number of recruited individuals should be increased in future studies to confirm the potential value 
of the protein indicators here described.
Related to the coverage of the urinary proteome achieved in this study, it is important to note that the main 
purpose was the identification of those proteins showing alteration in this clinical context. Knowing that, we 
compared our data with the “human urine” repository of PeptideAtlas, finding that 69% of the proteins identified 
here were not included in such repository and are thus complementary.
In conclusion, urine reflects molecular changes linked to albuminuria development in hypertensive patients 
with controlled blood pressure and novel clues in the association between immune response and hypertension 
are shown here. The silent and hidden albuminuria development is of special interest in the search of a better 
stratification of patients at risk so that a better preventive treatment could be designed and applied earlier. The 
molecular signature here identified in urine points to specific protein targets for novel therapeutic interventions 
in the management of hypertensives.
Methods
Patient selection and urine collection. Patient selection was based on a previous study showing the 
development of de novo albuminuria in patients during chronic RAS suppression9 and performed as described 
before46. Briefly, patients from the Hypertension Unit-Hospital 12 de Octubre were followed-up for a minimum 
of three years. At the end of that period patients were classified as follows: a) patients who remained normoal-
buminuric during the follow-up (N); b) patients developing de novo albuminuria during the follow-up (dnA); c) 
patients with maintained albuminuria since baseline and during the follow-up (MHA). Urine was collected at 
the end of the follow-up. A total of 100 hypertensives under RAS suppression, representative of the three groups, 
were included (46N, 29dnA and 25MHA). The study was approved by the Ethics Committee of the Hospital 12 de 
Octubre and was conducted according to the principles of the Declaration of Helsinki. All patients signed written 
informed consent before inclusion. N, dnA and MHA patients’ groups were compared by One-way ANOVA to 
identify significant differences in clinical characteristics or medication (Table 3). Urine samples were processed 
and stored as described before17, 18.
Quantitative iTRAQ-LC-MS/MS differential analysis. Protein digestion and isobaric labelling. Urine 
samples from a total of 37 hypertensive individuals under chronic RAS suppression were used for the quantitative 
differential analysis by liquid chromatography coupled to mass spectrometry in tandem (LC-MS/MS) (discovery 
phase). Isobaric tags for relative and absolute quantification experiment (iTRAQ, 8-plex) was performed as pre-
viously published16. Four biological replicates were analyzed per condition (N, dnA, MHA), combining aliquots 
of 1–4 samples per replicate. 150 μg of total protein from each biological condition were loaded in SDS-PAGE 
gels to concentrate all the proteins in a single band. Proteins were digested using the in-gel digestion protocol as 
Protein Uniprot Gene ID peptides
Variation rate
dnA/N MHA/N
Annexin A1 P04083 ANXA1 15 −2.8 −2.2
CD44 antigen P16070 CD44 9 −1.6 −1.9
Complement C3 P01024 C3 77 2.2 1.3
Protein S100-A8 P05109 S100A8 20 −3.3 −3.1
Protein S100-A9 P06702 S100A9 16 −2.4 −2.1
Table 2. Proteins with significant variation in urine by iTRAQ analysis in hypertensives under chronic 
RAS suppression developing albuminuria. Variation rate is expressed as the difference in average Zq values 
between groups, for the two comparisons (dnA/N and MHA/N). Zq values: log2-ratios expressed in form 
of the standardized variables. N: Normoalbuminuria; dnA: de novo albuminuria; MHA: maintained high 
albuminuria.
www.nature.com/scientificreports/
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previously described47. Briefly, gel bands were reduced with 10 mM DTT, alkylated in 50 mM iodoacetamide, and 
digested overnight at 37 C with 30 ng/mL modified trypsin (Promega, Madison, WI, USA) at 12:1 protein:trypsin 
(w/w) ratio in 50 mM ammonium bicarbonate, pH 8.8 containing 10% acetonitrile. The resulting tryptic peptides 
were extracted by incubation in 12 mM ammonium bicarbonate pH 8.8 and later, 0.5% trifluoroacetic acid (TFA). 
TFA was added to a final concentration of 1% and the peptides were desalted onto C18 Oasis-HLB cartridges 
and dried-down for further analysis. For stable isobaric labelling, the resulting tryptic peptides were dissolved 
in 100 mM Triethylammonium bicarbonate (TEAB) buffer, and the peptide concentration was determined by 
measuring amide bonds with the Direct Detect system (Millipore). Equal amounts of each peptide sample were 
labelled using the 8-plex iTRAQ Reagents Multiplex Kit (Applied Biosystems, Foster City, CA, USA) accord-
ing to manufacturer’s protocol. Normoalbuminuric, dnA and MHA samples were labelled with iTRAQ reagents 
Figure 4. ANXA1, C3, CD44, S100A8 and S100A9 showed significantly altered levels in urine from 
albuminuric patients by SRM-LC-MS/MS. Mann-Whitney test (95% confidence level) was applied.
Figure 5. Receiver operating curves (ROC) for the five confirmed proteins are shown, individually and 
combined. Responses were evaluated by analyzing N vs dnA, and N vs dnA + MHA. N: normoalbuminuria, 
dnA: de novo albuminuria, MHA: maintained high albuminuria.
www.nature.com/scientificreports/
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previously reconstituted with 70 μl of isopropanol. After incubation at room temperature for 2 h, reaction was 
stopped with 0.5% TFA, incubated for 30 min and peptides were combined. Samples were concentrated in a Speed 
Vac, desalted onto C18 Oasis-HLB cartridges and dried-down for further analysis. For increasing proteome cov-
erage, iTRAQ-labelled samples were fractionated by mixed-cation exchange chromatography (Oasis HLB-MCX 
columns) into six fractions, desalted and concentrated as before.
Figure 6. Graphs show correlations (Spearman correlation) between confirmed proteins and ACR (albumin to 
creatinine ratio).
Discovery Cohort Confirmation Cohort








(n = 11) P value
Age, y 63 ± 13 61 ± 9 60 ± 8 0.685 63 ± 10 68 ± 7 68 ± 10 0.078
Male sex, % 38 71 57 0.298 37 64 64 0.104
Current smoking, % 12 29 21 0.654 13 18 18 0.876
Diabetes, % 38 14 50 0.300 17 55 28 0.013*
Systolic blood pressure, mmHg 132 ± 14 135 ± 8 133 ± 18 0.879 139 ± 18 137 ± 21 137 ± 37 0.968
Diastolic blood pressure, mmHg 79 ± 13 83 ± 9 82 ± 10 0.705 82 ± 10 81 ± 10 77 ± 20 0.445
BMI, kg/m2 31 ± 5 29 ± 2 32 ± 5 0.344 30 ± 4 30 ± 5 29 ± 4 0.858
Albumin/creatinine, mg/g 9 ± 9 46 ± 38 72 ± 94 0.026* 6 ± 14 127 ± 198 374 ± 45 <0.0001*
Creatinine clearance rate, mg/mL 112 ± 39 114 ± 53 99 ± 34 0.724 195 ± 467 88 ± 45 59 ± 22 0.388
eGFR, mL/min/1.73 m2 83 ± 17 85 ± 23 78 ± 25 0.700 84 ± 16 67 ± 19 56 ± 21 <0.0001*
Total cholesterol, mg/dL 194 ± 30 158 ± 13 170 ± 20 0.004* 185 ± 32 165 ± 27 172 ± 32 0.062
Triglycerides, mg/dL 106 ± 50 124 ± 71 149 ± 87 0.249 122 ± 46 131 ± 64 99 ± 28 0.247
HDL cholesterol, mg/dL 57 ± 12 50 ± 19 44 ± 13 0.078 54 ± 13 49 ± 10 52 ± 14 0.420
LDL cholesterol, mg/dL 115 ± 28 83 ± 13 98 ± 17 0.008* 107 ± 31 89 ± 18 100 ± 23 0.050
Glycemia, mg/dL 103 ± 29 105 ± 12 109 ± 27 0.834 109 ± 25 120 ± 24 120 ± 42 0.305
Uric acid, mg/dL 5 ± 1 6 ± 2 7 ± 2 0.034* 5 ± 2 6 ± 2 7 ± 2 0.008*
ACEi, % 19 0 29 0.307 10 23 9 0.385
ARB, % 75 86 57 0.366 80 68 82 0.559
Diuretic, % 50 71 64 0.586 57 45 36 0.481
Calcium channel blocker, % 62 29 50 0.342 53 59 82 0.262
β blocker agent, % 19 14 36 0.463 30 32 18 0.706
α blocker agent, % 19 29 14 0.750 10 32 27 0.136
Anticoagulant, % 6 0 0 0.532 3 0 9 0.384
Lipid-lowering agent, % 69 57 86 0.355 80 82 64 0.470
Antidiabetic agent, % 31 14 43 0.438 10 36 18 0.068
Anti aldosteronics, % 0 14 29 0.075 17 18 9 0.795
Hypouricemic Agent, % 12 14 14 0.989 0 18 9 0.056
Table 3. Clinical characteristics of hypertensive patients under chronic RAS suppression included in the 
discovery (iTRAQ) and confirmation (SRM) cohorts. Values are expressed as mean ± SD or percentage (%). N: 
normoalbuminuria; dnA: de novo albuminuria; MHA: maintained high albuminuria.
www.nature.com/scientificreports/
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Protein identification and quantitation. Labelled peptides were analyzed by LC-MS/MS using a C-18 reversed 
phase nano-column (75 µm I.D. × 50 cm, 2 µm particle size, Acclaim PepMap RSLC, 100 C18; Thermo Fisher 
Scientific, Waltham, MA, USA) in a continuous acetonitrile gradient consisting of 0–30% B in 360 min, 50–90% 
B in 3 min (A = 0.1% formic acid; B = 90% acetonitrile, 0.1% formic acid). A flow rate of 200 nL/min was used 
to elute peptides from the nano-column to an emitter nanospray needle for real time ionization and peptide 
fragmentation on a Q-Exactive mass spectrometer (Thermo Fisher). An enhanced FT-resolution spectrum (res-
olution = 70,000) followed by the MS/MS spectra from the 15 most intense parent ions were analyzed along the 
chromatographic run. Dynamic exclusion was set at 40 s. For peptide identification, all spectra were analyzed with 
Proteome Discoverer (version 1.4.0.29, Thermo Fisher Scientific) using SEQUEST-HT (Thermo Fisher Scientific). 
For database searching at the Uniprot database containing all sequences from human and crap contaminants 
(March 06, 2013; 70024 entries), the parameters were selected as follows: trypsin digestion with 2 maximum 
missed cleavage sites, precursor and fragment mass tolerances of 2 Da and 0.02 Da, respectively, carbamidomethyl 
cysteine, iTRAQ modifications at N-terminal and Lys residues as fixed modifications, and methionine oxidation 
as dynamic modification. Peptide identification was validated using the probability ratio method48. False dis-
covery rate (FDR) was calculated using inverted databases, and the refined method49 with an additional filtering 
for precursor mass tolerance of 12 ppm50. Only peptides with a confidence of at least 95% were used to quantify 
the relative abundance of each peptide determined as previously described. Protein quantification from reporter 
ion intensities and statistical analysis of quantitative data to identify significant proteins were performed using 
QuiXoT based on a statistical model previously described51. In this model protein log2-ratios are expressed in 
form of the standardized variables, i.e., in units of standard deviation according to their estimated variances (Zq 
values). Individual protein responses to albuminuria development were evaluated. An average of Zq value of the 
four biological replicates was calculated per condition. Ratio of change between two conditions was expressed as 
the difference in average Zq values between compared groups (dnA/N and MHA/N).Those proteins with ratio of 
change between groups ≥|2|, and a minimum of 3 peptides identified were selected for further analysis.
System biology analysis. A system biology analysis of the whole set of identified proteins was per-
formed using a novel algorithm developed specifically for the analysis of coordinated protein responses in 
high-throughput quantitative proteomics experiments52. In this way, changes in functional biological processes 
produced by the coordinated protein behavior can be detected far beyond individual protein responses.
Briefly, this algorithm correlates the performance of a group of proteins inside of a category (biological pro-
cess) in terms of their quantitative behavior (relative abundance). As a result of this coordinated behavior, a Z 
value is assigned to each category together with a FDR rate. Categories including at least five proteins were con-
sidered. To identify the significant biological process altered in chronically treated hypertensive patients, dnA and 
MHA groups were compared to the N group applying restricted parameters and selecting those categories with a 
Z value ≥ |2| and FDR < 0.05. Protein pathway analysis was performed for the proteins identified in those catego-
ries of interest by STRING 9.053 consisting of a database of known and predicted protein interactions, including 
direct (physical) and indirect (functional) associations derived from genomics, high-throughput experiments and 
coexpression. High confidence filter (0.900) was applied.
Target protein analysis (Selected Reaction Monitoring (SRM)-LC-MS/MS). Urine samples from 
63 hypertensive patients under chronic RAS suppression were analyzed, individually (not pools), by label-free 
SRM-LC-MS/MS (selected reaction monitoring) as previously published (see Supplementary Table 8 for 
details)17, 18, 54, 55. Briefly, in-silico digestion of the protein of interest was done with Skyline software. Proteotypic 
peptides (confirmed by BLAST) were selected and analysis conditions were optimized by means of Skyline 
software. Transition masses (precursor ion and product ion), collision energy and fragmentor potential are 
then selected for confirmation analysis.Tryptic digest from 30 µg total protein were analyzed in a 6460 Triple 
Quadrupole LC/MS/MS on-line connected to nanoLC in a Chip-format configuration (ChipCube interface, 
Agilent Technologies) and 1200 Series LC Modules (Agilent Technologies). Peptide separation was carried out 
onto a ProtID Zorbax 300B-C18-5 μm chip with 43 × 0.075-mm analytical column and 40 nL enrichment column 
(Agilent Technologies). Two microliters of sample was injected at 3 μL/min and separation took place at 0.4 μL/
min as follow: 1) 0–3 min 5% B, 2) At 10 min 70% B, 3) At 12 min 95% B, 4) At 14 min 95% B, 5) 14.2–15 min 5% 
B (A = 0.1% formic acid in double-distilled water; B = 0.1% formic acid in acetonitrile). The fragmentor was set 
to 130 V, dwell time to 20 ms, delta EMV to 600 V, and collision energy was optimized for each SRM transition. 
The system was controlled by Mass Hunter LC–MS Acquisition Software (v4.01). Individual signals were nor-
malized based on TIC (total ion current) and normalized peak areas were calculated for inter-group comparison. 
Statistical analyses were performed by means of GraphPad Prism 6 (version 6.01) software. The ROUT method 
was applied to detect outliers based on the FDR, setting Q value to 5%. Mann-Whitney non-parametric test 
(95% confidence level) was performed. ROC curves were obtained considering all transitions for every protein 
(Supplementary Table 8) with Metabolanalyst software using ROC curve based model evaluation (Tester) and 
Random forest algorithm. Proteins were evaluated separately and combined, for the two comparisons: N vs dnA 
and N vs dnA + MHA.
References
 1. Blecker, S. et al. High-normal albuminuria and risk of heart failure in the community. Am. J. Kidney Dis. 58(1), 47 (2011).
 2. Gerstein, H. C. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. 
JAMA 286(4), 421 (2001).
 3. Arnlov, J. et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic 
individuals: the Framingham Heart Study. Circulation 112(7), 969 (2005).
www.nature.com/scientificreports/
1 0SCIENTIFIC REPORTS | 7: 8894  | DOI:10.1038/s41598-017-09042-2
 4. Mancia, G. et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial 
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31(7), 
1281 (2013).
 5. Pascual, J. M. et al. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 
64(6), 1228 (2014).
 6. Menne, J. et al. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up 
study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J. Am. Heart Assoc. 3(2), 
e000810 (2014).
 7. Haller, H. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N. Engl. J. Med. 364(10), 907 (2011).
 8. Bakris, G. L. & Molitch, M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 37(3), 867 (2014).
 9. Cerezo, C. et al. Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J. Hypertens. 
30(1), 204 (2012).
 10. Harrison, D. G. The immune system in hypertension. Trans. Am. Clin. Climatol. Assoc. 125, 130 (2014).
 11. Wenzel, U. et al. Immune Mechanisms in Arterial Hypertension. J. Am. Soc. Nephrol. 27(3), 677 (2016).
 12. Ryan, M. J. An update on immune system activation in the pathogenesis of hypertension. Hypertension 62(2), 226 (2013).
 13. McMaster, W. G. et al. Inflammation, immunity, and hypertensive end-organ damage. Circ. Res. 116(6), 1022 (2015).
 14. Schmaderer, C. & Heemann, U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs 
Arch. Pharmacol. 387(10), 905 (2014).
 15. Mattson, D. L. Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am. J. Physiol Renal Physiol 
307(5), F499–F508 (2014).
 16. Baldan-Martin, M. et al. Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New 
Predictors of Renal Damage and De Novo Albuminuria Indicators. Hypertension 68(1), 157 (2016).
 17. Gonzalez-Calero, L. et al. Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive 
patients under chronic renin-angiotensin system suppression. Cardiovasc. Diabetol. 15, 8 (2016).
 18. Martin-Lorenzo, M. et al. KLK1 and ZG16B proteins and arginine-proline metabolism identified as novel targets to monitor 
atherosclerosis, acute coronary syndrome and recovery. Metabolomics 11(5), 1056 (2015).
 19. Zubiri, I. et al. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free 
comparative analysis. J. Proteomics. 96, 92 (2014).
 20. Posada-Ayala, M. et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. 
Kidney Int. 85(1), 103 (2014).
 21. Varghese, S. A. et al. Urine biomarkers predict the cause of glomerular disease. J. Am. Soc. Nephrol. 18(3), 913 (2007).
 22. Barreiro, O. et al. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for 
adherent leukocytes. J. Cell Biol. 157(7), 1233 (2002).
 23. Gordon, S. Phagocytosis: An Immunobiologic Process. Immunity. 44(3), 463 (2016).
 24. Flannagan, R. S., Jaumouille, V. & Grinstein, S. The cell biology of phagocytosis. Annu. Rev. Pathol. 7, 61 (2012).
 25. Harrison, D. G. et al. Inflammation, immunity, and hypertension. Hypertension 57(2), 132 (2011).
 26. Engstrom, G. et al. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J. 
Hum. Hypertens. 21(4), 276 (2007).
 27. Magen, E. et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J. 
Clin. Hypertens. (Greenwich.) 10(9), 677 (2008).
 28. Nadar, S. K. & Lip, G. Y. New insights into complement C3 and inflammation in hypertension. J. Hum. Hypertens. 21(4), 261 (2007).
 29. Sheerin, N. S. et al. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J. 22(4), 
1065 (2008).
 30. Camussi, G. et al. In vivo localization of C3 on the brush border of proximal tubules of kidneys from nephrotic patients. Clin. 
Nephrol. 23(3), 134 (1985).
 31. Abbate, M. et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and 
complement-dependent interstitial inflammation in experimental renal disease. J. Am. Soc. Nephrol. 10(4), 804 (1999).
 32. Paravicini, T. M. et al. Dysregulation of vascular TRPM7 and annexin-1 is associated with endothelial dysfunction in inherited 
hypomagnesemia. Hypertension 53(2), 423 (2009).
 33. McArthur, S. et al. Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. J. Immunol. 185(10), 
6317 (2010).
 34. Tabe, Y. et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction 
of annexin A1. Cell Death. Differ. 14(8), 1443 (2007).
 35. Trott, D. W. & Harrison, D. G. The immune system in hypertension. Adv. Physiol Educ. 38(1), 20 (2014).
 36. Bai, F. et al. Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44-hyaluronan interaction in rats with 
hypertension and myocardial fibrosis. Life Sci. 153, 141 (2016).
 37. Wu, Y. et al. S100a8/a9 released by CD11b+ Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-Induced cardiac 
inflammation and injury. Hypertension 63(6), 1241 (2014).
 38. Barderas, M. G. et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J. 
Proteome. Res. 6(2), 876 (2007).
 39. Geczy, C. L., Chung, Y. M. & Hiroshima, Y. Calgranulins may contribute vascular protection in atherogenesis. Circ. J. 78(2), 271 
(2014).
 40. Pulido-Olmo, H. et al. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. Clin. 
Sci. (Lond) 130(7), 525 (2016).
 41. de la Cuesta, F. et al. A proteomic focus on the alterations occurring at the human atherosclerotic coronary intima. Mol. Cell 
Proteomics. 10(4), M110 (2011).
 42. de la Cuesta, F. et al. Deregulation of smooth muscle cell cytoskeleton within the human atherosclerotic coronary media layer. J. 
Proteomics. 82, 155 (2013).
 43. Castro, A. et al. APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. Atherosclerosis 
209(1), 201 (2010).
 44. Shioji, K. et al. Redox regulation by thioredoxin in cardiovascular diseases. Antioxid. Redox. Signal. 5(6), 795 (2003).
 45. Hilgers, R. H. et al. Thioredoxin reverses age-related hypertension by chronically improving vascular redox and restoring eNOS 
function. Sci. Transl. Med. 9(376) (2017).
 46. Gonzalez-Calero, L. et al. Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to 
predict albuminuria progression. Transl. Res. 178, 25 (2016).
 47. Bonzon-Kulichenko, E. et al. A robust method for quantitative high-throughput analysis of proteomes by 18O labeling. Mol. Cell 
Proteomics. 10(1), M110 (2011).
 48. Martinez-Bartolome, S. et al. Properties of average score distributions of SEQUEST: the probability ratio method. Mol. Cell 
Proteomics. 7(6), 1135 (2008).
 49. Navarro, P. & Vazquez, J. A refined method to calculate false discovery rates for peptide identification using decoy databases. J. 
Proteome. Res. 8(4), 1792 (2009).
www.nature.com/scientificreports/
1 1SCIENTIFIC REPORTS | 7: 8894  | DOI:10.1038/s41598-017-09042-2
 50. Bonzon-Kulichenko, E. et al. Revisiting peptide identification by high-accuracy mass spectrometry: problems associated with the 
use of narrow mass precursor windows. J. Proteome. Res. 14(2), 700 (2015).
 51. Navarro, P. et al. General statistical framework for quantitative proteomics by stable isotope labeling. J. Proteome. Res. 13(3), 1234 
(2014).
 52. Garcia-Marques, F. et al. A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative 
Proteomics. Mol. Cell Proteomics. 15(5), 1740 (2016).
 53. Jensen, L. J. et al. STRING 8–a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37 
(Database issue), D412–D416 (2009).
 54. Gonzalez-Calero, L. et al. Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient 
prognosis? Sci. Rep. 6, 19667 (2016).
 55. Martin-Lorenzo, M. et al. Cytoskeleton deregulation and impairment in amino acids and energy metabolism in early atherosclerosis 
at aortic tissue with reflection in plasma. Biochim. Biophys. Acta 1862(4), 725 (2016).
Acknowledgements
The authors acknowledge Lucía Guerrero and Maria Cruz Casal from Hospital 12 de Octubre for their 
participation in samples collection. Instituto de Salud Carlos III co- supported by FEDER grants (PI11/01401, 
PI13/01873, PI14/01650, PI16/01334, CPII15/00027, PT13/0001/0013, IF08/3667-1, PI11/02239, PI11/02432, 
PI14/0917, PI14/01841, PIE13/00045, CP15/00129, PI13/01746, REDinREN (RD12/0021/0001, RD12/0042/0071 
and RD16/0009)), and Fundación SENEFRO. These results are lined up with the Spanish initiative on the Human 
Proteome Project (SpHPP).
Author Contributions
M.M.L. and L.G.C. participated in urine analysis by iTRAQ, performed SRM-LC-MS/MS target analysis and 
carried out data analysis and interpretation. P.J.M. and M.B.M. contributed to iTRAQ data analysis. J.A.L. 
performed iTRAQ analysis. G.R.H. and F.C. participated in the study design and manuscript draft. JS participated 
in patients’ recruitment and samples management. J.V. participated in iTRAQ analysis. F.V., M.G.B., L.M.R. 
and G.A.L. participated in the conceived of the study, in its design and coordination and helped to draft the 
manuscript. All authors read and approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09042-2
Competing Interests: Dr. Ruilope has served as advisor/speaker for Astra-Zeneca, Bayer, Daiichi-Sankyo, 
Medtronic, Novartis, Pfizer, Relypsa, Sanofi, Takeda.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
